You are here: Industry Insights > Roche

News List

Is Roche's latest Tecentriq win really a win for Merck's Keytruda? fiercepharma
July 27, 2018
With new lung cancer data, Roche touted another win Thursday for red-hot immuno-oncology drug Tecentriq. But the way some analysts see things, it may actually be a win for archrival Keytruda.
Roche, PureTech team up to develop oral antisense oligonucleotides fiercebiotech
July 26, 2018
Roche has struck a deal with PureTech Health to develop oral antisense oligonucleotides....
Roche halts price hikes for 2018—but only after it already raised them twice fiercepharma
July 24, 2018
Roche joined a growing list of Big Pharma companies calling a halt to drug price increases—or cutting them—after President Donald Trump's naming and shaming. But that was after the Swiss drugmaker had already put through two rounds of price hikes this yea
PureTech Health Announces Collaboration with Roche americanpharmaceuticalreview
July 24, 2018
PureTech Health has entered into a multiyear collaboration with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.,
Roche's Tecentriq extends its hot streak with liver cancer combo breakthrough fiercepharma
July 19, 2018
Roche’s Tecentriq is on a much-needed hot streak.
US delay for Celltrion's Rituxan, Herceptin biosimilars pharmatimes
July 18, 2018
The US Food and Drug Administration has rejected Celltrion’s submissions for biosimilars to Roche drugs Rituxan and Herceptin.
Final NHS nod for Roche’s RoActemra pharmatimes
July 16, 2018
Roche/Chugai’s RoActemra should be routinely offered throughout the NHS to adults with giant cell arteritis (GCA) within the next three months, following a final green light from cost regulators.
Roche’s Venclexta filed in the US for acute myeloid leukemia pharmatimes
July 16, 2018
The submission is seeking approval for use of the drug, in combination with a hypomethylating agent or in combination with low dose cytarabine (LDAC), for treatment of people with previously untreated AML who are ineligible for intensive chemotherapy.
Roche’s Tecentriq/Cotellic study fails in colorectal cancer trial pharmatimes
July 09, 2018
Roche has revealed that a combination of Tecentriq and Cotellic tested in a late-stage trial failed to improve overall survival compared to regorafenib in patients with advanced metastatic colorectal cancer (CRC).
Roche's Tecentriq combo gives strong Phase 3 showing in triple negative breast cancer pharmafile
July 06, 2018
Roche has unveiled new Phase 3 data on its immunotherapy drug Tecentriq (atezolizumab) in combination with chemotherapy (Celgene’s Abraxane) as a first-line treatment

Previous page 1 2 3 4 5 6 7 8 9 10 ... 45 46 Next page